Market Research Future published an upcoming Research Report on Global Urinary
Tract Infection Market Research Report.
Market Scenario:
Urinary Tract Infection (UTI treatment) is the infection of the lower or upper urinary tract
caused by bacterial agents such as Escherichia coli, Staphylococcus saprophyticus, and
others. The symptoms associated with UTI are pain during urination, frequent urination and
a feeling of urination despite having an empty bladder.
Global Urinary Tract Infection (UTI) Treatment Market is valued at USD 8 billion in 2016,
which is expected to reach to USD 9.89 billion in 2023 at a CAGR of 3.6 %.
Get Sample Copy with Table and Figures included at
https://www.marketresearchfuture.com/sample_request/6138
Key players:
Bayer AG
GlaxoSmithKline Novartis AG
Dr. Reddy’s Laboratories Ltd
Pfizer Inc.
F. Hoffmann-La Roche Ltd
AstraZeneca
Cipla Inc.
Johnson & Johnson
and others.
Rise in Risk Factors Is the Prime Reason for Market Growth
The increase in risk factors for the UTI treatment market is unsafe sexual intercourse,
especially anal sex which favors transfer of infection, diseases such as diabetes which
results in lowering of immunity, obesity and a lack of hygiene and others. The incidence rate
of UTIs is 0.91 % of total population and 2.05 % for a female population with E.coli being
the most common pathogen accounting for 80 % to 90 % of all the cases.
Growth in Awareness Regarding Women Health and the High Economic Cost of the Disease
Is Driving a Large Demand
The World Health Organization (WHO) estimates that approximately 50 % of the women
suffer from UTI issues at some point in their lives resulting in more than 1 million
hospitalizations per year. Nearly 1 % of boys and 3 to 8 % of girls are diagnosed with UTI
treatment. The annual cost of UTI treatment infections treatment is higher than $1 billion in
the U.S. alone. Rise in hospital-borne infections, the emergence of drug-resistant bacteria,
growing geriatric population, childbirth, and increasing health awareness especially about
women health. According to Centres for Disease Control and Prevention among hospitals
acquired infections, approximately 75 % are associated with a urinary catheter.
Growth of Drug Resistance, Loss of Patents, Coupled With Increasing Market Fragmentation
May Hamper the Market Growth
The prime market constraints include growing drug resistance, unmet clinical needs, loss of
patents, increasing market fragmentation, and others.
Segments:
To generate a bird’s view of the global urinary tract infection market, the report is
segmented based on drug class, clinical indications, end users, and regions.
Based on drug class, the market is comprised of quinolones, aminoglycosides, β-lactam,
azoles, and others.
Based on clinical indications, this market is segmented into urethritis, cystitis, and
pyelonephritis and others.
Based on end users the market is segmented into hospitals, self-administered and others.
Based on the regions, the market is segmented as North America, Europe, Asia Pacific
Middle East and Africa and rest of the world.
Access Report at https://www.marketresearchfuture.com/upcoming-reports/urinary-tract-
infection-market-6138